Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Mosunetuzumab plus polatuzumab vedotin achieved an 88.1% objective response rate in heavily pretreated relapsed/refractory mantle cell lymphoma patients, including high-risk groups.

• Why it matters: Patients with relapsed/refractory MCL, especially after BTK inhibitor or CAR T-cell therapy, face poor outcomes, highlighting the need for more effective treatments with manageable safety profiles.
• What they did: A multicenter phase 2 trial enrolled 42 patients with a median of three prior therapies, administering mosunetuzumab and polatuzumab vedotin, and assessed response rates and safety over a median follow-up of 15.9 months.
• The result: The combination yielded high complete remission rates (78.6%) and a median progression-free survival of 18.6 months, with manageable cytokine release syndrome, supporting its potential for high-risk R/R MCL.